CBD reduced a "don't eat me" signal on leukemia cells and triggered cell death through a specific mitochondrial pathway

CBD reduced CD47 surface expression and triggered apoptosis in Jurkat leukemic cells. These effects were not blocked by cannabinoid receptor 2 agonists, antagonists, or anion channel blockers, but were significantly rescued by a VDAC-1 oligomerization inhibitor, revealing a specific mitochondrial pathway. Similar but weaker effects were observed in primary human T cells.

In vitro studies using Jurkat cells (T-cell acute lymphoblastic leukemia line) and human peripheral blood mononuclear cells under various culture conditions, CBD concentrations, and with or without different receptor agonists, antagonists, and channel blockers.

CD47 is a "don't eat me" signal that cancer cells use to avoid immune destruction. Understanding how CBD reduces this signal could inform new combination therapy approaches for aggressive blood cancers.

This adds mechanistic detail to the growing literature on CBD and cancer. By identifying the VDAC-1 oligomerization pathway, it moves beyond the general observation that CBD kills cancer cells to explaining how it might work.

In vitro study using cell lines may not reflect in vivo tumor biology. CBD also affected normal T cells, raising safety concerns for immunocompromised patients. Concentrations used may not be achievable in humans. No animal or clinical data.